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OBJECTIVES The purpose of this study was to determine long-term effects of stent-based paclitaxel delivery
on amount, rate and composition of neointimal thickening after stent implantation.
BACKGROUND Paclitaxel prevents vascular smooth muscle cell proliferation and migration in vitro and in
vivo. These actions, coupled with low solubility, make it a viable candidate for modulating
vascular responses to injury and prolonged effects after local delivery. We asked whether local
delivery of paclitaxel for a period of weeks from a stent coated with a bioerodible polymer
could produce a sustained reduction in neointimal hyperplasia for up to six months after
stenting.
METHODS Stainless steel stents were implanted in the iliac arteries of rabbits after endothelial
denudation. Stents were uncoated or coated with a thin layer of poly(lactide-co-S-
caprolactone) copolymer alone or containing paclitaxel, 200 mg.
RESULTS Paclitaxel release in vitro followed first-order kinetics for two months. Tissue responses were
examined 7, 28, 56 or 180 days after implantation. Paclitaxel reduced intimal and medial cell
proliferation three-fold seven days after stenting and virtually eliminated later intimal
thickening. Six months after stenting, long after drug release and polymer degradation were
likely complete, neointimal area was two-fold lower in paclitaxel-releasing stents. Tissue
responses in paclitaxel-treated vessels included incomplete healing, few smooth muscle cells,
late persistence of macrophages and dense fibrin with little collagen.
CONCLUSIONS Poly(lactide-co-S-caprolactone) copolymer-coated stents permit sustained paclitaxel delivery
in a manner that virtually abolishes neointimal hyperplasia for months after stent implanta-
tion, long after likely completion of drug delivery and polymer degradation. (J Am Coll
Cardiol 2000;36:2325–32) © 2000 by the American College of Cardiology
Attempts to attenuate restenosis after angioplasty using
systemic therapies have met with frustration. Driven by dual
goals of high local concentrations but low systemic expo-
sure, local delivery methods have been developed. As endo-
vascular stenting has become widespread, stents have been
proposed as ready means for local drug delivery. To date,
however, experimental stent-based drug delivery has not
been able to inhibit stent-induced intimal thickening (1–4)
although it has shown efficacy in reducing experimental
stent-induced thrombosis (1–3,5).
Limitations facing stent-based antirestenotic therapies
include complex multifactorial cellular and extracellular
matrix responses to stent-induced injury, adverse and exag-
gerated tissue responses to materials bound to stents and
brevity of contact between many delivered agents and target
vascular tissue. We asked whether many of these limitations
might be overcome via stent-based delivery of paclitaxel, a
diterpenoid compound and the active agent in the antineo-
plastic drug Taxol. Paclitaxel has diverse mechanisms of
action, including microtubule stabilization, arrest of cell
mitosis, retardation of cell migration and immunomodula-
tion (6) and has been reported to reduce vascular cell
proliferation and migration in vitro and in vivo (7–11).
Paclitaxel is also highly lipophilic and poorly soluble in
aqueous solution, making it an excellent candidate for
sustained delivery from stents and prolonged deposition in
atherosclerotic vessels. We used a stent-based polymer
delivery system to determine whether sustained delivery of
paclitaxel for weeks after stenting could alter intimal thick-
ening for months.
METHODS
Stents. Stainless steel stents (9 mm long 7-cell NIR stents,
Medinol Inc.) were left bare or coated with poly(lactide-co-
S-caprolactone) copolymer (pLA/pCL) with or without
paclitaxel 200 mg/stent, the maximum quantity possible
without disrupting the polymer scaffold’s integrity. After
sterilization, paclitaxel content for each stent was assessed
gravimetrically using the known mass proportions of pacli-
taxel and pLA/pCL in the coating. Stents with calculated
paclitaxel content .220 mg or ,180 mg were discarded.
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In vitro paclitaxel release kinetics. In vitro assays were
performed to assess the kinetics of paclitaxel release from
pLA/pCL-coated stents over 56 days. Fifteen stents were
coated with pLA/pCL loaded with paclitaxel, sterilized and
had initial paclitaxel load calculated gravimetrically (207 6
2 mg). Each stent was incubated in 15 mL of calf serum
(Gibco BRL, Life Technologies) at 37°C with constant
agitation at 120 rpm. Serum was changed twice daily for one
day and every one to two days thereafter to ensure sink
conditions. Three stents each at 1, 7, 14, 28 and 56 days
were removed from their release vials and analyzed for
residual paclitaxel content. Residual paclitaxel was extracted
using THF:DMAC, 50:50 by volume, and the polymer
precipitated in H20:ACN:Acetic acid; 90:10:0.1 (by vol-
ume). The resultant supernatant was analyzed for paclitaxel
content by HPLC (Metachem Taxsil column), and the
percent of initial paclitaxel released from each stent was
calculated.
Surgical procedure and tissue processing. All animal care
conformed to the “Position of the American Heart Associ-
ation on Research Animal Use,” was conducted in facilities
accredited by the American Association for Accreditation of
Laboratory Animal Care (AAALAC) and was approved by
the Institutional Animal Care and Use Committee
(IACUC) of MIT. Twenty-eight New Zealand White
rabbits (Millbrook Farm Breeding Labs), 3 to 4 kg, were fed
rabbit chow and water ad libitum. Aspirin (Sigma Chemical
Co, 0.07 mg/mL) was added to drinking water one day
before surgery and continued throughout the experiment.
Under anesthesia with ketamine (Fort Dodge Laboratories,
35 mg/kg IM) and xylazine (Miles Inc., 5 mg/kg IM), the
endothelium of both iliac arteries was denuded using a 3F
embolectomy catheter (Baxter Health Care Corp.) (2,12–
16). A metal stent mounted coaxially on a 3-mm angioplasty
balloon (10 mm Bandit, Boston Scientific Corp.) was passed
retrogradely into each iliac artery and expanded (15 s,
8 atm), yielding balloon:artery ratios of 1.1 to 1.2:1
(2,12,17). All animals received a single intravenous bolus of
standard heparin (100 U/kg, Elkins-Sinn Inc.) at the time
of stenting.
All animals survived until planned sacrifice. Iliac arteries
were harvested 3, 7, 28, 56 and 180 days after stenting.
Bromodeoxyuridine (BrdU) was administered (50 mg/kg
intravenously, Sigma Chemical Co.) 1 hour before sacrifice.
Under anesthesia with sodium pentobarbital, the inferior
vena cava was opened and perfusion performed via left
ventricular puncture with Ringer’s lactate solution followed
by 4% paraformaldehyde. Stented arterial segments were
embedded in methyl methacrylate mixed with n-butyl
methacrylate (Sigma Co.) and sectioned at 5 mm thickness
(13–15,18). Sections were taken from each end and the
middle of each stent. Vessels from animals sacrificed after
180 days were also sectioned just proximal and distal to the
stent.
Of 23 arteries implanted with uncoated stents, 2 were
harvested at 7, 10 at 28, 7 at 56 and 4 at 180 days. The ten
arteries that were implanted with stents coated with pLA/
pCL alone included two harvested at 7, four at 28 and four
at 56 days. Fifteen arteries receiving pLA/pCL-coated
paclitaxel-releasing stents included two harvested at 7, four
at 28, five at 56 and four at 180 days.
Histological analysis. All histological analyses were per-
formed by investigators blinded to stent type. Sections
stained with Verhoeff’s tissue elastin stain underwent
computer-assisted digital planimetery. Injury scores (19)
and neointimal, medial and external elastic lamina areas
were quantified for three cross sections per stent (proximal
end, middle and distal end), and the results were averaged.
For nonstented regions intimal:medial area ratios were
calculated. Proliferating medial cells were identified immu-
nohistochemically by uptake of BrdU (mouse anti-BrdU,
DAKO Co.), intimal macrophages by RAM-11 (DAKO
Co.), smooth muscle cell (SMC) by a-actin (mouse anti-
SMC a-actin, DAKO Co.), endothelial cells by factor VIII
related antigen (von Willebrand’s factor [vWF], goat anti-
human factor VIII, ICN Biomedicals, Inc.) and hyaluronan
by a biotinylated proteoglycan fragment (20) (gift of Dr. G.
Underhill, Georgetown School of Medicine). Standard
immunohistochemical protocols were followed as previously
described (13–15) with fibrin identified by Mallory’s PTAH
staining and collagen by picrosirius-red stain observed under
cross-polarized light (21).
Medial or intimal cell density was calculated by dividing
the number of nuclei by the medial or intimal area, the
number of BrdU positive or RAM-11 positive cells counted
and their prevalence in the media or intima calculated.
Smooth muscle cell, fibrin, hyaluronan and collagen staining
were scored from 0 to 4 (0 5 no stain present, 15 very
weak, 2 5 weak, 3 5 moderate and 4 5 intense) for staining
intensity and distribution.
Endothelial regrowth. The rate and completeness of en-
dothelial regrowth after denuding injury in this model is
variable and occurs late (17). Arteries harvested 180 days
after stent implantation were stained for vWF and scored
from 0 to 4 (0 5 no endothelial cells present, 15 ,25%,
2 5 25 to 50%, 3 5 50 to 75%, 4 to .75%) based on the
number of quadrants covered with vWF positive cellular
staining. To examine specifically the effects of bare or
paclitaxel-releasing stents (n 5 4 each) on endothelial cells
in vivo, stent implantation was performed in four animals in
vessels not subjected to balloon denudation. This method is
characterized uniformly by complete anatomic endothelial
restitution after three days (13,16). En face examination of
the completeness of endothelial surface coverage was per-
Abbreviations and Acronyms
BrdU 5 bromodeoxyuridine
pLA/pCL 5 poly(lactide-co-S-caprolactone) copolymer
SMC 5 smooth muscle cell
vWF 5 von Willebrand’s factor
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formed using silver staining (13,16). The area of intrastrut
surface covered with endothelium was measured using
digital planimetry and expressed as a percent of the total
stented segment surface area (16).
Statistics. All data are presented as mean 6 standard error.
Comparisons between the three treatment groups at each
time point used analysis of variance with Bonferroni/Dunn
correction for multiple comparisons. Data from the two
treatment groups examined at the six-month time point
were compared using Student t test. Values of p ,0.05 were
considered significant.
RESULTS
Stent-based paclitaxel release. Paclitaxel release from
pLA/pCL-coated stents was measured in serum. Release
followed first-order kinetics with minimal early burst and
little interstent variability: 36 6 10, 55 6 6, 63 6 2, 78 6
1, 91 6 1% released after 1, 7, 14, 30 and 56 days,
respectively.
Intimal thickening. The intimal response to stent implan-
tation at all time points was markedly altered by stent-
released paclitaxel. Qualitative differences were seen in
intimal composition and quantitative differences in intimal
mass. After seven days, the thin neointima of control or
pLA/pCL-coated stents were highly cellular, comprising
a-actin-positive SMC, RAM-11-positive macrophages and
extracellular matrix. In contrast, cellular organization was
absent after seven days in paclitaxel-treated arteries; the
internal elastic lamina remained largely exposed, covered
not by neointima but only by adherent inflammatory cells.
The areas around stent struts were fibrin-dense and rela-
tively free of infiltrating SMC (Fig. 1, A to C).
Neointimal area was markedly reduced 28, 56 and 180
days after implantation of paclitaxel-releasing stents.
Twenty-eight days after stent placement, the intima mea-
sured 0.98 6 0.11 and 1.28 6 0.10 mm2 in arteries receiving
uncoated and pLA/pCL-coated stents, respectively (p 5
NS). This was reduced over 50% to 0.40 6 0.07 mm2 in
stents releasing paclitaxel (p 5 0.004 and 0.0007 compared
with uncoated and pLA/pCL-coated stents, respectively,
Fig. 2, Table 1). The reduction in neointimal area was
sustained 56 days after stent implantation (neointimal areas
1.35 6 0.20 and 1.36 6 0.13 mm2 in uncoated and
pLA/pCL-coated stents, respectively, reduced by 60% to
0.50 6 0.07 mm2 in stents releasing paclitaxel, p 5 0.003
and 0.006 compared with uncoated and pLA/pCL-coated
stents, Fig. 1, D to I, and 2, Table 1). The effect of paclitaxel
persisted 180 days after stent implantation (neointimal area
0.56 6 0.06 and 0.96 6 0.11 mm2 in arteries receiving
paclitaxel-releasing or uncoated stents, respectively, p5
0.036, Fig. 3, Table 1). Injury scores were low and did not
differ between groups or over time.
There was no significant change in neointimal size in
arteries receiving paclitaxel-releasing stents between 56 and
180 days (0.50 6 0.07 and 0.56 6 0.06 mm2, respectively,
Fig. 2, Table 1) despite this period extending well beyond
Figure 1. Photomicrographs show rabbit iliac arteries stained with Verhoeff’s tissue elastin stain after balloon denudation and stent implantation. Seven days
after stenting, a thin cellular neointima separates the lumen from the internal elastic lamina in uncoated stents (A) and stents coated with
poly(lactide-co-S-caprolactone) (B). In arteries receiving stents coated with poly(lactide-co-S-caprolactone) containing paclitaxel (C), no intimal
thickening is seen although the media retains its cellularity. Fifty-six days after balloon denudation and stent implantation, neointimal thickening had
progressed in uncoated stents (D, G) and stents coated with poly(lactide-co-S-caprolactone) (E, H) but remained almost undetectable in stents coated with
poly(lactide-co-S-caprolactone) releasing paclitaxel (F, I). Original magnifications: A to F 5 1503, G to I 5 183.
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the anticipated in vivo completion of paclitaxel release and
degradation time for pLA/pCL. In uncoated stents neoin-
timal area fell slightly between 56 and 180 days (1.35 6 0.20
vs. 0.96 6 0.11mm2, p 5 0.20).
To examine for exacerbation of neointimal hyperplasia at
stent margins, segments of artery immediately adjacent to
the stent were examined in subjects sacrificed 180 days after
stent implantation. Intimal:medial area ratios did not differ
between arteries receiving uncoated stents (0.99 6 0.18) and
those receiving paclitaxel-releasing stents (1.03 6 0.17, p 5
NS).
Tissue responses. Differences in histologic responses to
control and paclitaxel-releasing stents were as pronounced
as the quantitative differences in neointimal area. Twenty-
eight, 56 and 180 days after stent implantation, the neoin-
tima in vessels receiving paclitaxel-releasing stents was thin
and sparsely cellular. Present on the luminal surface were
adherent inflammatory cells with no overlying intimal thick-
ening. Seven days after stent implantation, the time of peak
intimal and medial cell proliferation in this model (14),
uncoated stents provoked medial and intimal cell prolifera-
tion rates (BrdU positive cells) of 0.11 6 0.01% and 0.96 6
0.33%, respectively. These rates were reduced in paclitaxel-
releasing stents three-fold to 0.03 6 0.03% and 0.29 6
0.15%. Twenty-eight, 56 and 180 days after stent implan-
tation, BrdU-positive cells were infrequent, and their fre-
quency did not differ between groups.
The inflammatory response was evaluated using immu-
nohistochemical identification of RAM-11 positive tissue
monocyte/macrophages (Table 1). There was no significant
difference in intimal macrophage number between arteries
receiving uncoated and pLA/pCL-coated stents after 7, 28
Figure 2. Neointimal area (6 standard error) after balloon denudation and
stent implantation. Intimal areas 7, 28 and 56 days after implantation of
uncoated (open circles), poly(lactide-co-S-caprolactone)-coated (closed
circles) or poly(lactide-co-S-caprolactone)-coated paclitaxel-releasing
stents (solid squares). *p 5 0.004 and 0.0007 compared with uncoated and
poly(lactide-co-S-caprolactone)-coated stents, respectively, **p 5 0.003
and 0.006 compared with uncoated and poly(lactide-co-S-caprolactone)-
coated stents, respectively.





7 day macrophages (# cells RAM-111) 50 6 19 63 6 9 56 6 2
28 day intima (mm2) 0.98 6 0.11 1.28 6 0.10 0.40 6 0.07*
media (mm2) 0.25 6 0.04 0.19 6 0.03 0.23 6 0.04
macrophages (# cells RAM-111) 64 6 8 41 6 5 120 6 30†
56 day intima (mm2) 1.35 6 0.20 1.36 6 0.13 0.50 6 0.07*
media (mm2) 0.38 6 0.10 0.34 6 0.12 0.13 6 0.01‡
macrophages (# cells RAM-111) 57 6 9 82 6 14 168 6 39†
180 day intima (mm2) 0.96 6 0.11 0.56 6 0.06§
media (mm2) 0.25 6 0.03 0.15 6 0.02§
macrophages (# cells RAM-111) 6 6 4 157 6 25§
*p , 0.004 compared with uncoated and pLA/pCL-coated; †p , 0.04 compared with uncoated and pLA/pCL-coated; ‡p 5
0.07 compared with uncoated; §p , 0.04 compared with uncoated.
pLA/pCL 5 poly(lactide-co-S-caprolactone).
Figure 3. Photomicrographs show rabbit iliac arteries stained with Ver-
hoeff’s tissue elastin stain six months after balloon denudation and stent
implantation. (A) After uncoated stent implantation, a thick neointima
separates the lumen from the internal elastic lamina. (B) After implanta-
tion of a poly(lactide-co-S-caprolactone)-coated paclitaxel-releasing stent,
no neointima is present upon the internal elastic lamina with only a thin
cap covering the stent struts. Original magnification 5 2903.
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or 56 days. In uncoated stents there was a 10-fold fall in the
number of intimal macrophages between 56 and 180 days.
In paclitaxel-releasing stents, intimal macrophage numbers
were elevated after 28 and 56 days and did not fall
substantially between 56 and 180 days (Table 1). Macro-
phages were not seen in the arterial media.
We measured medial cross sectional area and cell density
in each group to assess possible late effects of inhibition of
medial SMC proliferation. Twenty-eight days after stent
implantation medial areas did not differ between groups
(Table 1). By 56 days medial area had fallen in arteries
receiving paclitaxel-releasing stents. After six months me-
dial area was still lower in arteries treated with paclitaxel
(0.15 6 0.02 mm2) compared with uncoated stents (0.25 6
0.03 mm2, p , 0.04). Medial cell densities, however, did
not differ significantly between treatment groups at any
time. Despite medial thinning and reduced cell density after
180 days in paclitaxel-treated vessels, no histologic evidence
of aneurysm formation, medial necrosis or vessel rupture
was seen in any artery. Overall arterial size (external elastic
lamina area) was no different in arteries receiving paclitaxel-
releasing stents compared with uncoated stents at any point
in time.
After 28 days the neointima within uncoated stents was
rich in SMC, collagen and hyaluronan, with little fibrin
(Table 2, Fig. 4, A to C). In contrast, in stents releasing
paclitaxel the neointima had markedly fewer SMC, less
hyaluronan and collagen and extensive fibrin (Table 2, Fig.
4, G to I). Between 28 and 180 days arteries receiving
uncoated stents gained neointimal collagen and lost hyalu-
ronan (Table 2, Fig. 4, D to F), while those receiving
paclitaxel-releasing stents showed persistent fibrin with
sparse neointimal collagen and few SMC (Table 2, Fig. 4, J
to L).
Endothelial cell regrowth. Because of the potent inhibi-
tory effects of stent-released paclitaxel on medial SMC
Table 2. Neointimal Extracellular Matrix Composition 28 or 180 days After Stent Implantation
Stent Coating
Fibrin (0–4) Collagen (0–4) Hyaluronan (0–4)
28 days 180 days 28 days 180 days 28 days 180 days
Uncoated 1.3 6 0.3 1.3 6 0.3 1.7 6 0.3 3.0 6 0.6 2.0 6 0.0 1.7 6 0.3
pLA/pCL 1.7 6 0.3 2.0 6 0.6 2.3 6 0.3
pLA/pCL-coated paclitaxel-releasing 4.0 6 0.0 4.0 6 0.0 1.0 6 0.0 1.7 6 0.3 2.7 6 0.3 2.7 6 0.3
pLA/pCL 5 poly(lactide-co-S-caprolactone).
Figure 4. Photomicrographs of rabbit iliac arteries after stent implantation. Serial sections from four arteries stained for collagen (picrosirius red), fibrin
(Mallory’s PTAH) and hyaluronan (b-PG). In arteries with uncoated stents, collagen deposition within the neointima (yellow-orange viewed under
polarized light) intensifies between 28 days (A) and 180 days (D). With paclitaxel-releasing stents, although medial collagen is present, neointimal collagen
is sparse after 28 (G) and 180 days (J). Neointimal fibrin (extracellular blue staining) is sparse in arteries receiving uncoated stents after 28 (B) and 180 days
(E). In contrast, intense extracellular fibrin persists in vessels receiving paclitaxel-releasing stents at 28 (H) and 180 days (K). Hyaluronan (brown staining)
diminishes in arteries with uncoated stents between 28 (C) and 180 days (F). In paclitaxel-releasing stents, hyaluronan persists without change between 28
(I) and 180 (L) days. *Sites of stent struts. Original magnification 1203.
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proliferation and intimal cell accumulation and the reported
lower sensitivity of endothelial cells to inhibition by pacli-
taxel in vitro (7), we investigated effects of stent-based
paclitaxel release on endothelial restoration. Endothelial
regrowth was variable and incomplete even 180 days after
denudation and uncoated stent-implantation. However, the
degree of vWF-positive cellular coverage was lower in
arteries implanted with paclitaxel-releasing stents than in
those receiving uncoated stents (1.0 vs. 2.7 quadrants
covered, respectively).
As we have previously reported, complete endothelial
regrowth does occur within three days if vessels are not
denuded before stenting (13). In this setting stent-based
paclitaxel release from pLA/pCL-coated stents did not
delay endothelial regrowth, with 100% of the surface cov-
ered with endothelium after three days in all control stents
and all pLA/pCL-coated paclitaxel-releasing stents.
DISCUSSION
Challenges that have faced stent-based drug delivery include
identifying a biological target, a material platform that does
not itself exacerbate proliferative, thrombotic or inflamma-
tory responses and an agent that can be delivered from the
platform so as to affect the chosen target. Our experiments
demonstrate that sustained delivery of paclitaxel for a period
of a few weeks from an endoluminal stent markedly atten-
uates stent-induced intimal thickening for at least six
months. In addition to quantitative reductions in neointimal
thickening, stent-based paclitaxel delivery also yields large
qualitative alterations in vascular responses to injury.
Prior studies. Previous work has addressed paclitaxel’s
effects on vascular repair after injury. Paclitaxel reduced rat
arterial SMC migration in vitro by 50% at 0.5 nM and by
100% at 100 nM (8). In vivo experiments demonstrated that
systemic administration of paclitaxel for five days (with peak
plasma concentrations of 50 to 60 nM) reduced neointimal
area by 70% 11 days after rat carotid artery injury. Axel et al.
(7) demonstrated that brief exposure to paclitaxel inhibited
growth and migration of human arterial SMC at concen-
trations of 0.01 to 10 mmol/L and examined in vivo the
effects of local delivery of paclitaxel via a microporous
balloon. Three groups have reported preliminary data that
stent-based paclitaxel delivery reduced stent-induced inti-
mal thickening up to 28 days after arterial injury (9–11).
Postulated mechanism of action. Paclitaxel’s efficacy may
reflect both its breadth of activities as well as its relative
insolubility. Paclitaxel interferes with cellular migration and
proliferation primarily by stabilizing microtubules (6).
Through this mechanism and others (22), it may interfere
with cells’ capacities to maintain shape, move, transmit
intracellular signals and effect intracellular transport. In
addition, paclitaxel may alter inflammatory cell activity,
directly linked to the genesis of stent-induced neointima
(14,15), by enhancing macrophage production of nitric
oxide, prostaglandins or other cytokines (23–29).
Tissue response. Histologic characterization of tissue re-
sponses in the presence of paclitaxel indicates arrest of
healing. Fibrin remains present for months, with little of the
collagen deposition or SMC infiltration characteristic of
uncoated stents. Of note is the sustained presence of
inflammatory cells as part of this delayed healing. The
number of monocyte/macrophages in the neointima of
arteries receiving uncoated stents fell dramatically after two
months, while in stents releasing paclitaxel even after six
months, macrophages persisted in the neointima in high
numbers. Although previous reports from our group have
connected early monocyte/macrophage recruitment with
intimal thickening (14,15), it does not appear as if the late
presence of these cells, i.e., between two and six months
after stent implantation, has the same implications. Of
concern, such incomplete healing may prolong the period of
vessel wall thrombogenicity, as has been suggested after
endovascular radiation therapy (30). While late thrombotic
events and delayed tissue growth were not observed in this
study, limitations of the model employed—with ligated
femoral arteries, consequent low flow velocities and lower
sheer-forces—will be essential to consider in translating our
findings to clinical evaluation. In contrast with responses
after stent-based radiation therapy, vessel segments at the
margins adjacent to the paclitaxel-releasing stent did not
reveal evidence of any marginal exacerbation or “candy-
wrapper effect.”
Comparison with other platforms and agents. Previous
attempts to combat restenosis with stent-based drug deliv-
ery have met with mixed results. While several biodegrad-
able and nonbiodegradable polymers have been shown to
provide a reservoir of sustained drug release in other clinical
settings, their use in coating endoluminal stents has typically
engendered a significant inflammatory and proliferative
tissue response (3,4,31,32). This response may be attributed
to effects of the polymer material or disruption of the
dynamic physiology of the luminal surface with bulky
material layers. Some stent-based drug delivery systems
have reduced the rate of thrombosis after injury (1–3,5) but
have failed to reduce either intimal thickening in experi-
mental models (1–3) or clinical restenosis (33). The polymer
material (pLA/pCL) used for stent coating in the current
experiments provoked no detectable increase in stent-
induced inflammation 56 days after implantation when
degradation had likely peaked.
Six months after stent implantation, no rebound en-
hancement of intimal thickening after paclitaxel release and
pLA/pCL degradation was seen. This strongly suggests
either that a two-month period of paclitaxel release in this
experimental model is sufficiently long to counteract the
cellular signals and mediators that follow stent-induced
arterial injury or that paclitaxel remains present and active
within the vessel wall long after delivery from the stent.
Because of the gap between completion of drug release and
six-month follow-up, our data make unlikely a late catch-up
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phenomenon whereby paclitaxel-treated arteries would de-
velop intimal thickening after cessation of drug activity.
Study limitations. This report of abrogation of intimal
thickening after stent-implantation warrants confirmation
and extension in alternative animal models. In particular,
studies of paclitaxel in settings of underlying arterial disease,
e.g. lipid-rich lesions or in settings of higher flow or more
severe deep arterial injury, e.g., the porcine coronary tree,
will be essential. In addition, although posing significant
technical challenges, studies of paclitaxel release, serum
concentration and tissue deposition in vivo will help eluci-
date the dynamic nature, location and duration of the
presence of released drug, which may enhance mechanistic
understanding of how paclitaxel inhibits intimal growth.
Such studies will be central to assessing safe and effective
doses of stent-based paclitaxel, as well as determining
potential risks of systemic toxicity in future clinical appli-
cations. Equally challenging will be characterization of
pLA/pCL degradation in vivo. Finally, the six-month
studies that addressed the hypothesis of long-term efficacy
of a combined system of polymer material and drug to-
gether, compared with uncoated control stents, did not
include polymer-only stents. The absence of vascular re-
sponses to stents coated with polymer material alone as late
as 56 days, when material degradation is likely complete,
makes the possibility of a later toxic polymer effect unlikely.
Conclusions. There has been long-standing hope that
stents might be able to carry with them their own ammu-
nition for attenuating stent-induced restenosis. To this end,
changes in stent design and material, or addition of
radiation-emitting isotopes, have been proposed. Perhaps
the most inherently appealing, yet technically challenging,
approach has been to add local drug treatment to the stent,
enabling it to treat directly the injured vessel. Our data,
demonstrating that stent-based delivery of paclitaxel can
virtually eliminate stent-induced tissue growth for months
after cessation of drug delivery, validate this approach as a
potential prevention for in-stent restenosis.
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